Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Long-Term Debt Repayments (2016 - 2018)

Gyre Therapeutics (GYRE) has disclosed Long-Term Debt Repayments for 9 consecutive years, with $5.1 million as the latest value for Q1 2018.

  • On a quarterly basis, Long-Term Debt Repayments fell 24.73% to $5.1 million in Q1 2018 year-over-year; TTM through Dec 2018 was $5.1 million, a 64.51% decrease, with the full-year FY2018 number at $5.1 million, down 64.51% from a year prior.
  • Long-Term Debt Repayments was $5.1 million for Q1 2018 at Gyre Therapeutics, up from $403000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $10.3 million in Q4 2016 to a low of $218000.0 in Q1 2014.
  • A 5-year average of $2.6 million and a median of $634000.0 in 2016 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: surged 1089.46% in 2016, then tumbled 96.07% in 2017.
  • Gyre Therapeutics' Long-Term Debt Repayments stood at $478000.0 in 2014, then surged by 80.54% to $863000.0 in 2015, then soared by 1089.46% to $10.3 million in 2016, then crashed by 96.07% to $403000.0 in 2017, then soared by 1161.04% to $5.1 million in 2018.
  • Per Business Quant, the three most recent readings for GYRE's Long-Term Debt Repayments are $5.1 million (Q1 2018), $403000.0 (Q4 2017), and $282000.0 (Q3 2017).